Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III, open-label, randomized, controlled, multiple-dose study of efficacy and safety of BMS-224818 as part of a quadruple drug regimen in first renal transplant recipients.

Next Previous
X
Search
Trial Profile

Phase II/III, open-label, randomized, controlled, multiple-dose study of efficacy and safety of BMS-224818 as part of a quadruple drug regimen in first renal transplant recipients.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 31 Jul 2017 Results of intent-to-treat post hoc analysis over ten years published in the American Journal of Transplantation
    • 03 Mar 2010 The US FDA's Cardiovascular and Renal Drugs Advisory Committee recommended approval of belatacept following a review of belatacept clinical development programme which included data from this trial, according to a Bristol-Myers Squibb media release.
    • 28 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top